Optimization of tncyclic antidepressant (TCA) therapy by dosage adjustments made in response to inappropriate concentrations in plasma or side effects can be extremely slow owing to the long half-lives of these drugs. I examine the practicality of alternative methods of arriving quickly and reliably at an adequate starting dosage. The clearance of a single test dose from plasma has been used to select individualized dosages before commencing therapy, but this takes several days and requires computer-assisted calculation of clearance. A simpler technique is to measure the concentration in a single timed plasma sample as an index of metabolism, and to infer the required dosage directly from a nomogram. Ideally, the nomograms should be interchangeable between patient populations and independent of the analytical method used, and the drug must have linear kinetics. Furthermore, TCAs are metabolized by common routes-demethylation and hydroxylation-so one might apply a single tolerance test for the entire class of drugs. Hydroxylation of TCAs can also be correlated with that of debrisoquine. The debrisoquine clearance test is non-invasive, faster, and analytically less demanding than TCA measurements. In the absence of rigid therapeutic ranges, tests that identify abnormally slow metabolizers may well be invaluable in preventing iatrogenic poisoning. Despite the usefulness of these methods in establishing effective initial dosages, their continued success depends upon good compliance, the maintenance of the patient's concurrent drug therapy, and a stable physical condition. In the non-ideal world, therefore, TDM cannot be dispensed with, but must be seen as an essential part of effective TCA treatment, based ultimately of course on sound clinical judgment.
The 30 years since the first tnicyclic antidepressant (TCA) was introduced have seen a number of additions to this class of drug. Some 25 compounds are now available for prescription worldwide. Although some of the newer drugs offer advantages in terms of severity of side effects and safety when taken in overdose, none appears to have improved therapeutic efficacy over imipramine.
Consequently the established drugs (imipramine, desipramine, amitriptyline, and nortriptyline) are still commonly prescribed, accounting for a 46% share of TCA prescriptions in the U.S.A. in 1986 (1). However, improvement rates remain at only about 65%, as compaIed with a placebo response rate often in the region of 35%. In attempts to both improve response rate and decrease the incidence of side effects, some laboratories have introduced a therapeutic drug monitoring (TDM) service for TCAs. The recent dramatic improvements in analytical techniques make these measurements much easier and consequently more widely available than originally envisaged (2,3). Here, I discuss the rationale for TDM, and assess the usefulness of some alternative methods that might be applied to regulating TCA dosage during therapy.
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The Rationale for TDM
There are two quite different situations in which it is convenient and more meaningful to measure the clinical effect of a drug rather than its concentration in plasma. First, where the drug binds irreversibly with receptors, its clinical effects may persist long after the drug has been eliminated from the body. The monoamine oxidase inhibitors are examples of such drugs, which are said to have a "hit-and-run" effect. The second situation arises when the clinical action of the drug is easily and reliably measured. For example, it is more usual to assess anticoagulation therapy by determining prothrombin time rather than by measuring the drug concentration in plasma. However, there are situations where such an approach is clearly less than satisfactory, and plasma drug-concentration measurements must be considered as a possible approach to improving the efficacy of treatment.
For therapeutic monitoring to be cost effective, at least some of the following conditions must be fulfilled:
(a) The clinical end-point is not easily measured or may be slow to appear, or the drug may be given prophylactically.
(b) The clinical response can be related to the drug concentration in plasma.
(c) There is a wide intenindividual variability in the drug concentrations that appear in plasma after a standard dose is ingested, which is not readily related to the patient's physical characteristics.
(d) The therapeutic index (ratio of minimum toxic to minimum effective concentration) is low.
(e) The symptoms of insufficient medication are not easily distinguished from those of drug toxicity.
(/) The development of toxic side effects may have particular risks for some patients.
(g) Metabolism is altered by disease or infection.
For some drugs (nortriptyline, imipramine, and amitriptyline), a relationship between the concentration in plasma and therapeutic effect has been established-at least in some groups of patients-which can serve as the practical basis of this approach. Although controversy exists for other TCA drugs, a considerable amount of the differences in findings between studies can be eliminated when treatment variables other than drug concentration are identified: differences in diagnostic criteria, study design, range of observed drug concentrations in plasma, etc. Alterations in pharmacokinetics from disease, such as increased drug protein binding, can be assessed (4, 5) , and the effects of concomitant drug therapy can be monitored (6, 7) . TCA side effects such as orthostatic hypotension are of particular concern in the elderly patient with brittle bones, and the severity of these can be related to the drug concentration in plasma (8) . There is therefore a sound rationale for using TDM as a guide to regulating the dose in TCA therapy, and several review articles examine these points in more detail (9) (10) (11) .
The traditional approach to TCA therapy has been to select an average starting dose of drug, and then gradually increase the dose until the desired therapeutic effect is If these can be assessed in advance of treatment, then the potential exists to apply this information to dosage-selection procedures. Obviously, any technique that can reliably select an appropriate dosage regime at the outset of therapy is advantageous, and I describe and evaluate several alternative procedures in this paper.
Debnsoquine Phenotyping
Some people have an impaired ability to convert debrisoquine to its major metabolite, 4-hydroxydebrisoquine, the The debrisoquine phenotyping test is easily performed (16). After administration of a 10-mg dose of debrisoquine, urine is collected over the next 8 h. Concentrations of unchanged debrisoquine and of the 4-hydroxy metabolite in the urine are measured, and the ratio of debrisoquine to 4-hydroxydebrisoquine is calculated. The population falls into two distinct categories: extensive metabolizers (ratio 0-8) and poor metabolizers (ratio >21). Classi1ring patients in thl8 way has been discussed previously as a means of identi1ing those patients most at risk of developing druginduced toxicity (17) . Ayesh et al. (18) have shown nortriptyline metabolism to be significantly impaired in volunteer subjects previously classified as poor metabolizers of debrisoquine, as compared with extensive debrisoquine metabolizer volunteers. Halflife is increased (mean value 42 h vs 14 h) and clearance is decreased (mean value 2.1 mL/min vs 5.4 mLfmin), and there was no overlap in values between the two groups of volunteers. Potter et al. (19) noted that the incidence of low concentrations of 2-hydroxydesipramine in plasma and of a 2-hydroxydesipramine/desipramine ratio <1/30 is about the same as the incidence of poor hydroxylation of debrisoquine. Although the hydroxylation of amitriptyline is under similar control (20) , amitriptyline demethylation is not correlated with debrisoquine hydroxylation (21). Information as to debrisoquine phenotype is of little value in identifring patients who may be at risk of toxicity from tertiary-amine TCAs, which are primarily demethylated before hydroxylation. This is confirmed by the finding that the profiles of plasma concentration vs time for axnitriptyline and imipramine do not differ significantly in extensive and poor debrisoquine metabolizers (18) . Furthermore, it appears that it is only the production of the cis-or E-(the predominant) isomer rather than the trans-or Z-isomer that is related to debrisoquine hydroxylation, implying that different enzymes are involved in these two hydroxylations (22) .
Using a slightly more sophisticated approach than simple categorization into extensive and poor metabolizer phenotypes, one can use the actual value of the debrisoquine metabolic ratio (debrisoquine/4-hydroxydebrisoquine) and relate this directly to TCA metabolism. For example, the ratio for the concentrations of 2-hydroxydesipramine and desipramine in urine was also found to correlate with the debrisoquine metabolic ratio (23) . Bertilsson and Aberg. Wistedt (24) have also demonstrated a good correlation between steady-state concentrations of desipramine in plasma and the debrisoquine metabolic ratio in 10 depressed patients treated with 75 mg twice daily for two weeks. Furthermore, nortriptyline and desipramine clearance have been shown to correlate negatively with the debrisoquine/ 4-hydroxydebrisoquine ratio, and desipramine half-life is positively related to this ratio (25,26).
Thus debrisoquine phenotyping appears to be a useful tool for identifying fast and slow metabolizers of those TCAs for which hydroxylation is the main route of metabolism. This test is easy to perform, even on an outpatient basis, but there have been no reports of its use to prospectively select dosage regimes for individual patients.
Inter-Drug Metabolism
It has been shown in cross-over studies that the rates of metabolism of desipramine and nortriptyline correlate strongly within individuals (27, 28). There was a strong correlation between the half-life and steady-state concentration of nortriptyline and desipramine. Similarly, Mellstrom et al. (29) studied steady-state concentrations of amitriptyline and clomipramine in 15 patients. Reciprocal steadystate concentrations of amitriptyline and clomiprainine (tertiary-amine parent compounds) and nortriptyline and desmethylclomipramine (secondary-amine metabolites) in plasma were highly correlated. Ziegler et al. (30, 31 ) were unable to demonstrate a correlation in half-life or clearance between the tertiary amine doxepin and the secondary amine protriptyline. A similar observation was made with maprotiline and imipramine in five elderly volunteers (32). This is to be expected, because the tertiary amine is demethylated and the secondary amine is hydroxylated.
It should be stressed that the existence of such correlations, however strong they may be, does not mean that drugs can be interchanged on a milligram for milligram basis, for TCAs have different bioavailabilities [1.7 for nortriptyline:desipraniine, 1.4 for clomipramine:amitriptyline, and 2.6 for desmethylclomipramine:nortriptyline (28, 29) ]. These relationships have to be worked out in advance for each pair of drugs, which would involve studying patients who are receiving sequential courses of treatment with different drugs; such opportunities are seldom readily available. Thus if the kinetic characteristics of one of these drugs in a subject are known, it is possible to predict the kinetics of the other compound if they are metabolized by the same predominant route. There are, however, no studies in the literature that use this information to select dosages of TCAs when medication is changed from one drug to another. The rationale for this approach is simple: measurements made after giving a small challenge or test dose of the chosen drug before treatment is actually begun are used to assess the individual patient's handling of the drug. A suitable maintenance dosage is selected to achieve a target steady-state concentration, to avoid toxicity while at the same time ensuring that each patient receives adequate drug exposure. For such an approach to be practical, the drug under study must fulfill the criteria for TDM set out above, and in addition meet three other important considerations. First, the drug elimination half-life must be fairly long, somewhere in excess of 10-15 h. Because it takes about five halllives on chronic dosing to reach steady-state, this can be reached quickly without the use of a pharmaco- which may be expected to be considerably extended in patients. The second requirement is that the drug does not exist in a form that may be given as an intravenous bolus dose, because this again enables steady-state to be reached quickly. Third, the drug must display linear pharmacokinetics, because only then can measurements made at one dosage be used to predict concentrations at another dosage.
As early as 1972, Alexanderson These nomograms (Table 1) This modification produces a much quicker result, and is less intrusive on the patient.
The time chosen at which to make the concentration measurement must obviously be a compromise between theoretical and practical considerations. The size of the dose that can be given without excessively sedating the patient or causing other adverse effects must be titrated against the limit of accurate and reliable measurement of the concentration in plasma. Consideration must also be made of the schedule's application to clinical conditions, so as not to disrupt routine patient management. From a theoretical stance the optimal time for sampling will be 1.44 times the mean population half-life for the drug. This is important, because if the terminal elimination phase is not established at the sampling time, errors may occur, as shown in Figure  1 . This figure contains data from Braithwaite et al. (34) in which the patient group has been divided on the basis of their nortriptyline half-life. In the group with the longer half-life (>36 h), it is probable that the terminal elimination phase was not properly established when the 24-h specimen was drawn, which would result in an underestimation of optimal dosage, because the 24-h concentration would be fhlsely increased.
The difference between the slopes of the regression lines is quite marked (4.3 at <36 h half-life and 7.1 at >36 h), making almost a 50% discrepancy in steadystate concentration where the 24-h concentration is 50 pgIL. This hypothesis is strengthened by the fact that the subdivision of patients in this way considerably improves the correlation over that of the group taken as a whole. More- Table 2 . Despite the differences in patient characteristics and concomitant drug therapy, both studies produced an almost identical result in terms of the steady-state amitriptyline plus nortriptyline concentration achieved. However, the dosages administered were significantly lower, and the demethylation rate (ratio of nortriptyline to amitriptyline) was much lower in the elderly group. This finding complements earlier work on TCA metabolism in elderly patients (9) . Both these studies also gave results that were some 15% lower than expected, and the nomogram has been revised accordingly, as shown in Table 3 . Table 4 shows the results of all prospective dosing studies. These methods are shown to be more reliable than traditional methods in arriving at concentrations in plasma that are within the target range. This aspect was specifically ad- Individual dosage selection for imipramine and desipramine has also been studied. In retrospective studies, similar results have been obtained correlating steady-state concentrations with either single-dose clearance or 24-h concentrations (45) (46) (47) . There are only two prospective studies, both with desipramine (44, 45) , and these are included in Table 4 . As with amitriptyline, it was the 24-h value for imipramine plus desipramine combined concentration that best correlated with steady-state concentration after therapy with imipramine (47) . A recent report (48) describes a study in which 17 elderly patients were given a 30-mg test dose of mianserin, followed by 30mg daily for four weeks. Using both 16-and 24-h single-dose measurements and relating mianserin concentrations alone or in combination with desmethylmianserin to those achieved at steady-state, no simple relationship could be found on which to base a dosage prediction test. The reason for this apparent discrepancy is unclear, but Gram et al. (10) have suggested that mianserin may be able to induce its own metabolism. Clearly, further investigations are required in this area.
The success of these tolerance tests hinges upon the important assumption that the kinetics of the drugs are not dose-dependent; i.e., that the clearance and steady-state concentration does not alter disproportionately to any alteration in dosage. This assumption appears valid for both ainitriptyline and nortriptyline over a wide range of dosages, drug concentrations in plasma, and patient categories (4,9). There is, however, accumulating evidence that desipramine kinetics are saturable, with steady-state concentrations increasing over and above that predicted from the dosage increase. For example, Bjerre et al. (49) treated seven elderly patients with increasing doses of imipramine and found steady-state desipramine concentrations to be 1.25 to 2.2 times higher than predicted when the dosagewas increased; in contrast, plasma imiprainine concentrations increased as expected. Nelson and Jatlow (50), in a larger study of 42 patients, observed about one third of their sample to have linear desipraniine kinetics, another third to have some saturating effect, and the remaining third a significant (>50%) effect when treated with increasing doses of desipramine. The mechanism of this is uncertain, because there are conflicting reports of both linear (50, 51) and nonlinear (52) increases in steady-state concentrations of the major metabolic product of desipramine, 2-hydroxydesipramine.
There are also reports of autoinduction: i.e., the drug is able to stimulate its own metabolism. Nelson et al. (53) present two patients who were unable to maintain steadystate desipramine concentration, and there are reports of a minority of patients with declining doxepin concentrations in their blood despite a constant maintained dose (54) . But these reports are rare compared with those which show dose-dependent kinetics.
Discussion
Three different approaches have been assessed in this paper for their practical application to the selection of optimal dosage regimes for TCA therapy. The first of these, the debrisoquine phenotyping test, is an indirect measure of an individual's TCA metabolism. The test is easy to perform, takes only 8 h, and does not require expert analytical skills. In its crudest form, the test can be used solely to identi1r those patients with extremely slow TCA metabolism who may be at particular risk of developing toxic side effects. The absolute value of the debrisoquine metabolic ratio can also be correlated with TCA metabolism, for example with steady-state concentration, clearance, hydroxylation rate, etc. In theory, the debrisoquine metabolic ratio should be able to predict the dosage required by an individual to achieve a target steady-state concentration, but it has not yet found clinical application. It is important to note that the usefulness of this test would be limited to those TCAs that are metabolized primarily by hydroxylation rather than by demethylation (for example, nortriptyline and desipramine).
The second possibility for dosage selection rests on the assumption that if two drugs are metabolized by the same enzyme system, then knowledge of the handling of one drug can be used to predict that of the other. The potential for the use of this relationship is limited, because even the two isomers of 10-hydroxynortriptyline are produced by different enzymes. While such relationships are academically interesting, they are clearly limited in their practical application. Relatively few patients have their therapy altered in this way, and there are logistical difficulties in setting up the data base from which to draw such relationships. However, this might be achieved more simply by measuring, for example, 24-h concentrations of different TCAs after a single dose in a group of volunteer subjects, with use of a crossover study design. Once the precise nature of the relationship between dosage and the concentrations of the different drugs in plasma is established in a group of individuals, it might be possible to use a test dose of nortriptyline, for example, to determine an optimal dosage of desipra.mine.
As far as I have ascertained, the third of these dosage selection methods is the only one to have been used in prospective dosing studies. In this approach one makes a single or a series of carefully timed drug-concentration measurements in plasma after administration of a challenge or test dose of the chosen drug. This scheme has been quite successfully used in achieving observed steady-state plasma drug concentrations within or near their target ranges. Results are limited by inaccuracies in the analytical methodology and also by the range of strengths of tablets available. However, while the observed concentrations may not always be in perfect agreement with the predicted values, they do greatly decrease the variability in steadystate concentrations over that seen when a standard dose is prescribed. It is unlikely that greater precision is required, because the therapeutic ranges are often not well defined but are advocated in terms of reducing the likelihood of drug-induced toxicity. The tolerance tests are easy to perform, especially the single-point 24-h method, and treat-ment i8 not appreciably delayed. While these methods of selecting optimal dosages of TCAs for the treatment of individual patients have had some success,the successof their widespread use is limited by two constraints, viz., patient compliance with the prescribed dose and the presence of other active drug metabolites.
Most TDM and dose prediction procedures for TCA therapy account for only the parent drug, and in the case of the tertiary amines the active demethylated metabolite also. In recent years the hydroxylated metabolites of these compounds have received considerable attention. They have been shown to have roughly equivalent antidepressant potency in inhibiting noradrenalin or serotonin re-uptake (though not necessarily the same specificity of action) as the parent compounds (55) (56) (57) . The hydroxylated metabolites appear to be present in plasma in concentrations similar .to those of the parent compounds, and they have been implicat.-ed in the production of side effects, particularly cardiotoxicity (52, (58) (59) (60) . This would suggest that methods that are unable to assess the contribution made by these metabolites to response, toxicity, and ultimately to dosage selection are less than adequate. It should be pointed out, however, that attempts to relate antidepressant effect to steady-state concentrations of some of the hydroxylated metabolites have not been successful so far (61) (62) (63) .
Studies on patient compliance show that between a quarter and a half of all outpatients simply do not take their medication. Other types of compliance problems, which may be even more frequent, include taking medications for the wrong reasons, and errors in dosage and timing. Furthermore, patients may sometimes take medications prescribed for other members of the household, risking possible pharmacokinetic or pharmacological interactions (64, 65) .
Conciusion
The methods assessed in this paper for selection of optimal dosage regimes for TCAs appear less than satisfactory in the light of observations that the patient is unlikely to take the medication as prescribed, and that there are probably active metabolites present in the plasma that are not accounted for. However, the choice of an initial dosage based on a pharmacokinetic principle does provide significant advantages over either using a standard dosage in all patients or making some allowance for observed physical characteristics.
Furthermore, if pharmacokinetic methods are used, TDM can play an important role in checking on compliance, because if the observed steady-state plasma concentration falls far short of that predicted, poor compliance can be suspected and the patient can be challenged. Thus both dosage-prediction tests and TDM have important roles in ensuring effective treatment of depression, and should be used as a supplement to good clinical judgment rather than as a substitute for it.
